Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inflamed Language: FDA Sends Harsh Warning Letter To Allergan For Acne Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Allergan gets slammed for Aczone Gel promotional claims that FDA says are backed by data "not even nominally statistically significant."

You may also be interested in...



FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit

DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.

FDA And Allergan Resume Promotional Battle After Settling First Amendment Suit

DDMAC letter objects to direct mail piece implying Lumigan is superior to Xalatan in lowering intraocular pressure. FDA had cited Allergan for similar claims in 2005.

DDMAC Gets Aggressive On Downplaying Risk Info, Sends Three Letters In Three Weeks

Materials aimed at patients and professionals targeted in letters to Iroko, Eisai and Shire.

Related Content

Topics

UsernamePublicRestriction

Register

PS069888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel